Iron‐chelating therapy with deferasirox in transfusion‐dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre studyPellegrino Musto, Alessandro Levis, Luca Maurillo et al.|British Journal of Haematology|2017Cited by 25
Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical–Biological Entity?Alessia Campagna, Roberto Latagliata, Daniela De Benedittis et al.|Journal of Clinical Medicine|2022Cited by 4
Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical-Biological Entity?Daniela De Benedittis, Roberto Latagliata, Luana Fianchi et al.|Blood|2018Cited by 2
Myelodysplastic Neoplasms Patients' and Caregivers' Unmet Needs and Their Impact on Their Quality of Life and SymptomsElena Crisà, Esther Natalie Olíva, Elisa Diral et al.|Blood|2024Cited by 0
Unmet Needs and Their Impact on Quality of Life and Symptoms in Myelodysplastic Neoplasm Patients and CaregiversElena Crisà, Esther Natalie Olíva, Daniela Cilloni et al.|Preprints.org|2025Cited by 0